The Italian National External Quality Assessment Program in Cytogenetics

4 years of activity (2013-2016) following the introduction of poor performance criteria

Maria Chiara de Stefano, Giovanna Floridia, Federica Censi, Fabrizio Tosto, Marco Salvatore, Alessandro Civolani, Barbara Crescenzi, Daniela Giardino, Elisabetta Lenzini, Ermanna Lisi, Fortunato Lonardo, Marco Mancini, Antonio Novelli, Giuseppe Piombo, Sabine Stioui, Domenica Taruscio

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Italian External Quality Assessment (IEQA) Program in Cytogenetics, established in 2001 by the Istituto Superiore di Sanità (ISS), covers both Constitutional and Oncohaematological diagnosis. In 2013, performance criteria were defined and adopted. In this paper, we present the data from the first 4 years of activity (2013-2016) following the introduction of performance criteria.

METHODS: The enrollment is voluntary, fee-based and open to both public and private Italian laboratories. The scheme is annual and retrospective; a national panel of experts assess technical, analytical and interpretative performance.

RESULTS: Overall, 95 distinct Italian laboratories participated in different Cytogenetics IEQA schemes over the 2013-2016 years and most of the laboratories took part in Constitutional diagnosis. General hospitals and local health centers represented 40% of the total participants and the percentage of laboratories from Northern Regions was more than 45% of total participants throughout the 4-year period. As regards the performance evaluation, on average, 11, 9 and 23% of participants were marked as poor performers in Prenatal, Postnatal and Oncohaematological schemes, respectively. With regard to critical errors, ISCN nomenclature in Prenatal and Postnatal schemes, and interpretation in Oncohaematological diagnosis, were identified as main issues. On the other hand, karyotype errors and inadequate analysis decreased strongly, over the 4 years, in Constitutional and Oncohaematological diagnosis, respectively.

CONCLUSIONS: Our data show that the introduction of poor performance encourages laboratories to address critical issues, and the IEQA participation helps to improve quality in cytogenetic testing.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalAnnali dell'Istituto Superiore di Sanita
Volume54
Issue number2
DOIs
Publication statusPublished - Jun 20 2018

Fingerprint

Cytogenetics
Fees and Charges
Karyotype
Terminology
General Hospitals
Health

Cite this

The Italian National External Quality Assessment Program in Cytogenetics : 4 years of activity (2013-2016) following the introduction of poor performance criteria. / de Stefano, Maria Chiara; Floridia, Giovanna; Censi, Federica; Tosto, Fabrizio; Salvatore, Marco; Civolani, Alessandro; Crescenzi, Barbara; Giardino, Daniela; Lenzini, Elisabetta; Lisi, Ermanna; Lonardo, Fortunato; Mancini, Marco; Novelli, Antonio; Piombo, Giuseppe; Stioui, Sabine; Taruscio, Domenica.

In: Annali dell'Istituto Superiore di Sanita, Vol. 54, No. 2, 20.06.2018, p. 109-116.

Research output: Contribution to journalArticle

de Stefano, Maria Chiara ; Floridia, Giovanna ; Censi, Federica ; Tosto, Fabrizio ; Salvatore, Marco ; Civolani, Alessandro ; Crescenzi, Barbara ; Giardino, Daniela ; Lenzini, Elisabetta ; Lisi, Ermanna ; Lonardo, Fortunato ; Mancini, Marco ; Novelli, Antonio ; Piombo, Giuseppe ; Stioui, Sabine ; Taruscio, Domenica. / The Italian National External Quality Assessment Program in Cytogenetics : 4 years of activity (2013-2016) following the introduction of poor performance criteria. In: Annali dell'Istituto Superiore di Sanita. 2018 ; Vol. 54, No. 2. pp. 109-116.
@article{3c0cad41759c4c62b0ef4916a2bd7fd1,
title = "The Italian National External Quality Assessment Program in Cytogenetics: 4 years of activity (2013-2016) following the introduction of poor performance criteria",
abstract = "BACKGROUND: Italian External Quality Assessment (IEQA) Program in Cytogenetics, established in 2001 by the Istituto Superiore di Sanit{\`a} (ISS), covers both Constitutional and Oncohaematological diagnosis. In 2013, performance criteria were defined and adopted. In this paper, we present the data from the first 4 years of activity (2013-2016) following the introduction of performance criteria.METHODS: The enrollment is voluntary, fee-based and open to both public and private Italian laboratories. The scheme is annual and retrospective; a national panel of experts assess technical, analytical and interpretative performance.RESULTS: Overall, 95 distinct Italian laboratories participated in different Cytogenetics IEQA schemes over the 2013-2016 years and most of the laboratories took part in Constitutional diagnosis. General hospitals and local health centers represented 40{\%} of the total participants and the percentage of laboratories from Northern Regions was more than 45{\%} of total participants throughout the 4-year period. As regards the performance evaluation, on average, 11, 9 and 23{\%} of participants were marked as poor performers in Prenatal, Postnatal and Oncohaematological schemes, respectively. With regard to critical errors, ISCN nomenclature in Prenatal and Postnatal schemes, and interpretation in Oncohaematological diagnosis, were identified as main issues. On the other hand, karyotype errors and inadequate analysis decreased strongly, over the 4 years, in Constitutional and Oncohaematological diagnosis, respectively.CONCLUSIONS: Our data show that the introduction of poor performance encourages laboratories to address critical issues, and the IEQA participation helps to improve quality in cytogenetic testing.",
author = "{de Stefano}, {Maria Chiara} and Giovanna Floridia and Federica Censi and Fabrizio Tosto and Marco Salvatore and Alessandro Civolani and Barbara Crescenzi and Daniela Giardino and Elisabetta Lenzini and Ermanna Lisi and Fortunato Lonardo and Marco Mancini and Antonio Novelli and Giuseppe Piombo and Sabine Stioui and Domenica Taruscio",
year = "2018",
month = "6",
day = "20",
doi = "10.4415/ANN_18_02_06",
language = "English",
volume = "54",
pages = "109--116",
journal = "Annali dell'Istituto Superiore di Sanita",
issn = "0021-2571",
publisher = "Istituto Superiore di Sanita",
number = "2",

}

TY - JOUR

T1 - The Italian National External Quality Assessment Program in Cytogenetics

T2 - 4 years of activity (2013-2016) following the introduction of poor performance criteria

AU - de Stefano, Maria Chiara

AU - Floridia, Giovanna

AU - Censi, Federica

AU - Tosto, Fabrizio

AU - Salvatore, Marco

AU - Civolani, Alessandro

AU - Crescenzi, Barbara

AU - Giardino, Daniela

AU - Lenzini, Elisabetta

AU - Lisi, Ermanna

AU - Lonardo, Fortunato

AU - Mancini, Marco

AU - Novelli, Antonio

AU - Piombo, Giuseppe

AU - Stioui, Sabine

AU - Taruscio, Domenica

PY - 2018/6/20

Y1 - 2018/6/20

N2 - BACKGROUND: Italian External Quality Assessment (IEQA) Program in Cytogenetics, established in 2001 by the Istituto Superiore di Sanità (ISS), covers both Constitutional and Oncohaematological diagnosis. In 2013, performance criteria were defined and adopted. In this paper, we present the data from the first 4 years of activity (2013-2016) following the introduction of performance criteria.METHODS: The enrollment is voluntary, fee-based and open to both public and private Italian laboratories. The scheme is annual and retrospective; a national panel of experts assess technical, analytical and interpretative performance.RESULTS: Overall, 95 distinct Italian laboratories participated in different Cytogenetics IEQA schemes over the 2013-2016 years and most of the laboratories took part in Constitutional diagnosis. General hospitals and local health centers represented 40% of the total participants and the percentage of laboratories from Northern Regions was more than 45% of total participants throughout the 4-year period. As regards the performance evaluation, on average, 11, 9 and 23% of participants were marked as poor performers in Prenatal, Postnatal and Oncohaematological schemes, respectively. With regard to critical errors, ISCN nomenclature in Prenatal and Postnatal schemes, and interpretation in Oncohaematological diagnosis, were identified as main issues. On the other hand, karyotype errors and inadequate analysis decreased strongly, over the 4 years, in Constitutional and Oncohaematological diagnosis, respectively.CONCLUSIONS: Our data show that the introduction of poor performance encourages laboratories to address critical issues, and the IEQA participation helps to improve quality in cytogenetic testing.

AB - BACKGROUND: Italian External Quality Assessment (IEQA) Program in Cytogenetics, established in 2001 by the Istituto Superiore di Sanità (ISS), covers both Constitutional and Oncohaematological diagnosis. In 2013, performance criteria were defined and adopted. In this paper, we present the data from the first 4 years of activity (2013-2016) following the introduction of performance criteria.METHODS: The enrollment is voluntary, fee-based and open to both public and private Italian laboratories. The scheme is annual and retrospective; a national panel of experts assess technical, analytical and interpretative performance.RESULTS: Overall, 95 distinct Italian laboratories participated in different Cytogenetics IEQA schemes over the 2013-2016 years and most of the laboratories took part in Constitutional diagnosis. General hospitals and local health centers represented 40% of the total participants and the percentage of laboratories from Northern Regions was more than 45% of total participants throughout the 4-year period. As regards the performance evaluation, on average, 11, 9 and 23% of participants were marked as poor performers in Prenatal, Postnatal and Oncohaematological schemes, respectively. With regard to critical errors, ISCN nomenclature in Prenatal and Postnatal schemes, and interpretation in Oncohaematological diagnosis, were identified as main issues. On the other hand, karyotype errors and inadequate analysis decreased strongly, over the 4 years, in Constitutional and Oncohaematological diagnosis, respectively.CONCLUSIONS: Our data show that the introduction of poor performance encourages laboratories to address critical issues, and the IEQA participation helps to improve quality in cytogenetic testing.

U2 - 10.4415/ANN_18_02_06

DO - 10.4415/ANN_18_02_06

M3 - Article

VL - 54

SP - 109

EP - 116

JO - Annali dell'Istituto Superiore di Sanita

JF - Annali dell'Istituto Superiore di Sanita

SN - 0021-2571

IS - 2

ER -